MedTrace Logo

Open Label Study Telmisartan and Amlodipine in Hypertension

NCT00614380 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 976

Last updated 2014-02-13

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5 mg (T80/A5) during long-term open-label treatment.

Conditions

Interventions

DRUG

telmisartan/amlodipine 40/5 mg fixed combination

DRUG

telmisartan/amlodipine 80/5 mg fixed combination

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-03-31

Countries

  • Belgium
  • Canada
  • Denmark
  • Finland
  • France
  • Netherlands
  • Norway
  • Philippines
  • South Africa
  • South Korea
  • Sweden
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614380 on ClinicalTrials.gov